CURRIULUM VITAE Frank B. Furnari
Work Address: Ludwig Institute for Cancer Research & University of California, San Diego CMM-E, Room 3053 9500 Gilman Drive La Jolla, CA 92093-0660 Phone: (858) 534-7809 (lab), -7819 (office) Fax: (858) 534-7750 e-mail: [email protected]
Date and Place of Birth: May 30, 1964, Queens, New York
Education: B.A. awarded: May, 1985 in Biology, Hofstra University, Hempstead, New York
Ph.D. awarded: January, 1993 in Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina
Professional History: 1987-1993: Graduate student, Microbiology and Immunology, University of North Carolina: Chapel Hill, NC. 2/93-7/00: Postdoctoral fellow, Ludwig Institute for Cancer Research & University of California, San Diego; La Jolla, CA. 8/00-4/07: Assistant Investigator and Head of the Section of Human Carcinogenesis: Ludwig Institute for Cancer Research-San Diego 4/07-11/11: Associate Investigator and Head of the Section of Human Carcinogenesis: Ludwig Institute for Cancer Research-San Diego 11/11-6/15: Senior Investigator and Head of the Section of Human Carcinogenesis: Ludwig Institute for Cancer Research-San Diego 6/15-12/15: Senior Investigator and Head Laboratory of Tumor Biology: Ludwig Institute for Cancer Research-San Diego 1/16-present: Member and Head Laboratory of Tumor Biology: Ludwig Institute for Cancer Research-San Diego
7/01-6/07: Assistant Adjunct Professor, UCSD Department of Medicine 7/07-10/11: Associate Adjunct Professor, UCSD Department of Medicine 3/01-9/05: Associate Member, UCSD Moores Cancer Center 10/05-present: Participating Member, UCSD Moores Cancer Center 7/10-present: Faculty member T32 GM008666: Basic and Clinical Genetics 9/11-present: Supervisory committee T32 CA009523: Growth Regulation and Oncogenesis 9/15-present: Faculty member T32 CA121938: Cancer Cell Biology 11/11-present: Professor (tenured), UCSD Department of Pathology 11/11-present: Head of Neuro-oncology Research in the Division of Neuropathology, UCSD
Honors and Awards: 11/92 Travel Grant, American Association for Cancer Research 8/92 Travel Grant, NIH 1991 Travel Grant, University of North Carolina 1994-1997 The Robert Steel Foundation for Pediatric Cancer Research Fellowship 1999 AACR Young Investigator Award 1999 Pediatric Brain Tumor Foundation Travel Award 2001 Kimmel Faculty Scholar Award 2002 V Foundation Scholar Award 2005 Goldhirsh Foundation Grant 2010 Society for Neuro-Oncology Award for Excellence in Adult Basic Research 2011 Society for Neuro-Oncology Award for Excellence in Translational Research 2011 Rubinstein Achievement in Neuropathology Award 2012 European Association for Cancer Research- Molecular Insights into Invasion and Drug Resistance- proffered paper award 2016 MD Anderson: 2016 Deborah M. Richman Lecture 2016 Selected co-chair 2017 Society for Neuro-Oncology annual meeting 2017 Society for Neuro-Oncology Scientific program co-chair
Publications: Furnari, F. B., Adams, M. D., and Pagano, J. S. Regulation of the Epstein-Barr Virus (EBV) DNA Polymerase Gene. J. Virol 66:2837-2845,1992.
Furnari, F. B., Adams, M. D. and Pagano, J. S. Novel Processing of the 3' End of the EBV DNA Polymerase mRNA. PNAS 90:378-82, 1993.
Furnari, F. B., Quinlivan, E. B., Kenney, S., and Pagano, J. S. RAZ, An Epstein-Barr Virus Transdominant Repressor That Modulates The Viral Reactivation Mechanism. J. Virol 68: 1827- 1836, 1994.
Arap, W., Nishikawa, R., Furnari, F. B., Cavenee, W. K., Huang, H-J. S. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 55: 1351-1354, 1995.
Nishikawa, R., Furnari, F. B., Ling, H., Arap, W., Berger, M. S., Cavenee, W. K., Huang, H-J. S. Loss of p16INK4 expression is frequent in high grade gliomas. Cancer Res 55: 1941-1945, 1995.
Furnari, F. B., Lin, H., Huang, H.-J. S., Cavenee, W. K. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. PNAS 94: 12479-12484, 1997.
Robertson, G. P., Furnari, F. B., Miele, M. E., Glendening, M. J., Welch, D. R., Fountain, J. W., Lugo, T. G., Huang, H.-J. S., Cavenee, W. K. In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. PNAS 95: 9418-9423, 1998.
Carethers, J. M., Furnari, F. B., Zigman, A. F., Lavine, J. E., Jones M. C., Graham, G. E., Teebi, A. S., Huang, H.-J. S., Ha, H. T., Chauhan, D. P., Chang, C. L., Cavenee, W. K., Boland, C. R. Absence of PTEN/MMAC1 Germline mutations in sporadic Bannayan-Riley-Ruvalcaba Syndrome. Cancer Res. 58: 2724-2726, 1998.
Furnari, F. B., Huang, H.-J. S., Cavenee, W. K. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res. 58: 5002-5008, 1998.
Wick, W., Furnari, F. B., Naumann, U., Cavenee, W. K., Weller, M.W. PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis. Oncogene 18:3936-3943, 1999.
Bogler, O., Furnari, F. B., Kindler-Roehrborn, A., Sykes, V. W., Yung, R., Huang, H.-J. S., Cavenee, W. K. SETA: a novel SH3 domain-containing adapter molecule associated with malignancy in astrocytes. Neuro-Oncology 2:6-15, 2000.
Reiss, K., Wang, J.-Y., Romano, G., Furnari, F. B., Cavenee, W. K., Morrione, A., Tu, X., Baserga, R. IGF-1 receptor signaling in a prostatic cancer cell line with a PTEN mutation. Oncogene 19:2687-2694, 2000.
Fan, X., Furnari, F. B., Cavenee, W. K., Castresana, J. S. Non-isotopic silver-stained SSCP is more sensitive than automated direct sequencing for the detection of PTEN mutations in a mixture of DNA extracted from normal and tumor cells. Int J Cancer. 18:1023-1026, 2001.
Chuenkova, M. V., Furnari, F. B., Cavenee, W. K., Pereira, M. A. Trypanosoma cruzi trans- sialidase: A potent and specific survival factor for human schwann cells via phosphatidylinositol 3-kinase/Akt signaling. PNAS 98: 9936-9941, 2001.
Klingler-Hoffmann, M, Fodero-Tavoletti, M. T., Mishima, K., Narita, Y., Cavenee, W. K., Furnari, F. B., Huang, H.-J. S., Tiganis, T. The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor. JBC 276: 46313-46318, 2001.
De Smet, C., Nishimori, H., Furnari, F. B., Bogler, O., Huang, H.-J. S., Cavenee, W. K. A novel seven transmembrane receptor induced during the early steps of astrocyte differentiation identified by differential expression. J. Neurochem. 81:1-14, 2002
Narita, Y., Nagane, M., Mishima, K., Huang, H.-J. S., Furnari, F. B., Cavenee, W. K. Mutant Epidermal Growth Factor Receptor signaling down-regulates p27 through activation of the Phosphatidylinositol 3-kinase/Akt pathway in Glioblastomas. Cancer Res. 62: 6764-6769, 2002.
Schmidt, M. H. H., Furnari, F. B., Cavenee, W. K., Bogler, O. Epidermal growth factor receptor signaling intensity determines intracellular protein interactions, ubiquitination, and internalization. PNAS 100: 6505-6510, 2003.
The HGCP/CGAP Consortium. The Generation and Utilization of a Cancer Oriented Representation of the Human Transcriptome, Using Expressed Sequence Tags. PNAS 100: 13418-13423, 2003.
Shah, J. V., Botvinick, E., Bonday, Z., Furnari, F., Berns, M., Cleveland, D. W. Dynamics of centromere and kinetochore proteins: implications for checkpoint signaling and silencing. Current Biology 14: 942-952, 2004.
Schmidt, M. H. H., Hoeller, D., Yu, J., Furnari, F. B., Cavenee, W.K., Dikic, I., Bogler, O. Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by the Cbl- SETA/CIN85 complex. MCB 24: 8981-8993, 2004.
Nishikawa, R., Suigiyama, T., Narita, Y., Furnari, F., Cavenee, W. K., Matsutani, M. Immunohistochemical analysis of the mutant epidermal growth factor, DEGFR, in glioblastoma. Brain Path, 21: 53-56, 2004.
Okumura, K., Zhao, M., DePinho, R.A., Furnari, F.B., Cavenee, W.K. Cellular Transformation by the MSP58 Oncogene is Inhibited by its Physical Interaction with the PTEN Tumor Suppressor. PNAS 102: 2703-2706, 2005.
Gao, T., Furnari, F., Newton, A.C. PHLPP: a Novel Phosphatase that Directly Dephosphorylates Akt, Promotes Apoptosis, and Suppresses Tumor Growth. Molecular Cell 18: 13-24, 2005.
Perera, R. m., Narita, Y., Furnari, F. B., Tavarnesi, M. L., Luwor, R. B., Burgess, A. W., Stockert, E., Jungbluth, A. A., Old, L. J., Cavenee, W. K., Scott, A. M., Johns, T. G. Treatment of Human Tumor Xenografts with Monoclonal Antibody 806 in Combination with a Prototypical Epidermal Growth Factor Receptor-Specific Antibody Generates Enhanced Antitumor Activity. Clin Cancer Res 11: 6390- 6399, 2005.
Carrasco, D. R., Fenton, T., Protopopova, M., Sukhdeo, K., German, M., You, M., Divicio, D., Nogueira, C., Stommel, J., Fletcher, C., Hornick, J. L., Cavenee, W. Furnari, F., DePinho, R. A. PTEN and Ink4a/Arf tumor suppressors maintain a myelolymphoid hematopoietic compartment and cooperate to constrain histocytic sarcoma development. Cancer Cell, 9:379-90, 2006.
Sok, J. C., Coppelli, F. M., Thomas, S. M., Lango, M, N., Xi, S., Hunt, J. L., Freilino, M. L., Graner, M. W., Wikstrand, C. J., Bigner, D. D., Gooding, W. E., Furnari, F. B., Grandi, J. R. Mutant Epidermal Growth Factor Receptor (EGFRvIII) Contributes to Head and Neck Cancer Growth and Resistance to EGFR Targeting. Clinical Cancer Research, 12: 5064-5073, 2006.
Okumura, K., Mendoza, M., Bachoo, R. M., DePinho, R. A., Cavenee, W. K., Furnari, F. B. PCAF regulates the PI3-kinase signaling pathway by acetylating PTEN. JBC, 281: 26562-26568, 2006 (paper of the week).
Johns, T. G., Perera R. M., Vernes, S. C., Vitali A. A., Cao, D. X., Cavenee, W. K., Scott, A. M., Furnari F. B. The Efficacy of EGFR-Specific Antibodies Against Glioma Xenografts is Influenced by Receptor Levels, Activation Status and Heterodimerization. Clinical Cancer Research, 13: 1911-1925, 2007 (cover of issue).
Huang, P. H., Mukasa, A., Bonavia, R., Flynn, R. A., Zachary E. Brewer Z. E., Cavenee, W. K., Furnari, F. B*, White, F. M.* Quantitative Analysis of EGFRvIII Cellular Signaling Networks Reveals a Novel Combinatorial Therapeutic Strategy for Glioblastoma. PNAS 104: 12867-12872, 2007 (* co- corresponding authors).
Wiedemeyer, R., Brennan, C., Heffernan, T. P., Xiao, Y., Mahoney, J., Protopopov, A., Zheng, H., Furnari, F., Cavenee, W. K., Hahn, W. C., Ichimura K., Collins V. P., Chu, G. C., Stratton, M. R., Ligon, K. L., Futreal, P. A., and Lynda Chin, L. Compensatory Feedback Circuit among of INK4 Tumor Suppressors Constrains Glioblastoma Development in Human. Cancer Cell, 13: 355-365 (2008).
Read, R. D., Cavenee, W. K., Furnari, F. B., and Thomas, J. B. A Drosophila model for EGFR-Ras and PI3K dependent human glioma. PloS Genetics. 5: e1000374 (2009).
Mukherjee, B., McEllin, B., Camacho, C., Tomimatsu, N., Sirasanagandala, S., Nannepaga, S., Hatanpaa, K., Mickey, B., Madden, C., Maher, E., Boothman, D., Furnari, F., Cavenee, W., Bachoo, R., and Burma, S. EGFRvIII and DNA Double-Strand Break Repair: A Molecular Mechanism for Radioresistance in Glioblastoma. Cancer Res., 15: 4252-4259 (2009).
Lu, K., Zhu, S., Cvrljevic, S., Huang, T., Sarkaria, S., Akhavan, D., Dang, J., Dinca, E., Plaisier, S., Oderberg, I., Lee, Y., Chen, Z., Caldwell, J., Xie, Y., Loo, J., Seligson, D., Chakravarti, A., Lee, F., Weinmann, R., Cloughesy, T., Nelson, S., Bergers, G., Graeber, T., Furnari, F., James, C.D., Cavenee, W., Johns, T., and Mischel, P. Fyn and Src are Effectors of Oncogenic EGFR Signaling in Glioblastoma Patients. Cancer Res., 17: 6889-6898 (2009).
Mukasa, A., Wykosky, J., Ligon, K. L., Chin, L., Cavenee, W. K., Furnari, F. Mutant EGFR is Required for Maintenance of Glioma Growth In Vivo, and Its Ablation Leads to Escape from Receptor Dependence. PNAS. 107: 2616-2621 (2010). Highlighted by: The Medial News; UC Newsroom; ScienceDaily; HealthCanal; UCSD The Guardian; and Bio-Medicine.
Huang, PH., Miraldi, E. R., Xu, A. M., Kundukulam, V. A., Del Rosario, A. M., Flynn, R. A., Cavenee, W. K., Furnari, F. B., White, F. M. Phosphotyrosine signaling analysis of site-specific mutations on EGFRvIII identifies determinants governing glioblastoma cell growth. Mol. Biosyst. 6: 1227-37 (2010).
Nitta, M., Kozono, D., Kennedy, R., Stommel, J., Ng, K., Zinn, P.O., Kushwaha, D., Kesari, S., Inda M. D., Wykosky, J., Furnari, F., Hoadley, K.A., Chin, L., Depinho, R.A., Cavenee, W.K., D'Andrea, A., Chen, C.C. Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy. PLoS One, 5: May (2010).
Inda, M. Bonavia, R., Mukasa, A., Narita, Y., Sah, D. W. Y, Vandenberg, S., Brennan, C., Johns, T. G., Bachoo, R., Hadwiger P., Tan, P., DePinho, R. A., Cavenee, W., and Furnari, F. Tumor Heterogeneity is an Active Process Maintained by a Mutant EGFR-induced Cytokine Circuit in Glioblastoma. Genes & Development, 24: 1731-45 (2010).
Staquicini, F., Ozawa, M. Moya, C., Driessen, W., Barbu, E. M., Nishimori, H., Soghomonyan, S., Flores, L. II, Liang, X., Paolillo, V., Alauddin, M., Basillion, J., Furnari, F., Bogler, O., Lang, F., Aldape, K., Fuller, G., Hook, M., Gelovani, J., Sidman, R., Cavenee. W.K., Pasqualini, R., Arap,W. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J. Clin Invest, 121: 161-73, 2011.
Chumbalkar, V., Latha, K., Hwang, Y.H., Maywald, R., Hawley, L., Sawaya, R., Diao, L., Baggerly, K., Cavenee, W.K., Furnari, F.B., Bogler, O. Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of ∆EGFR. J. of Proteome Res, 10: 1343-52, 2011.
Wang, Y., Huang, J. W., Li, M., Cavenee, W. K., Mitchell, P. S., Zhou, X., Tewari, M., Furnari, F. B., Taniguchi, T. MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. Mol cancer Res, 9:1100-1111, 2011.
Cvrljevic, A. N., Akhavan, D., Wu, M., Martinello, P., Furnari, F. B., Johnston, A. J., Guo, D., Pike, L., Cavenee, W.K., Scott, A. M., Mischel, P. S., Hoogenraad, N.J, Johns, T. G. Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: implications for glucose metabolism. J Cell Sci, 124:2938-50, 2011.
Hu, J., Jo, M., Cavenee, W. K., Furnari, F., Vandenberg, S. R., Gonias, S. L. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells. PNAS. 108: 15984-15989 (2011).
Feng H, Hu B, Liu KW, Li Y, Lu X, Cheng T, Yiin JJ, Lu S, Keezer S, Fenton T, Furnari FB, Hamilton RL, Vuori K, Sarkaria JN, Nagane M, Nishikawa R, Cavenee WK, Cheng SY. Activation of Rac1 by Src-dependent phosphorylation of Dock180Y1811 mediates PDGFRa- stimulated glioma tumorigenesis in mice and humans. J. Clin Invest, 121:4670-84, 2011.
Li, M., Mukasa A., Inda, M-d-M., Zhang, J. Chin, L., Cavenee, W., Furnari, F. Guanylate binding protein-1 is a novel effector of EGFR-driven invasion in glioblastoma. JEM. 208: 2657-73, 2011.
Bonavia, R., Inda, M-d-M., Vandenberg, S., Cheng, S-Y., Nagane, M., Hadwiger, P., Tan, P., Sah, D. W.Y., Cavenee, W., Furnari, F. EGFRvIII promotes glioma angiogenesis and growth through the NF- kB, interleukin-8 pathway. Oncogene, 31: 4054-4066 (2012).
Feng, H., Hu, B., Jarzynka, M.J., Li, Y., Keezer, S., Johns, T.G., Tang, C.K., Hamilton, R.L., Vuori, K., Nishikawa, R., Sarkaria, J.N., Fenton, T., Cheng, T., Furnari, F.B., Cavenee, W.K., Cheng, S-Y. Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. PNAS, 109: 3018-23, 2012.
Fenton, T.R., Nathanson, D., Ponte de Alberquerque, C., Kuga D., Iwanami, A., Dang, J., Yang, H., Tanaka, K., Oba-Shinjo, S.M., Uno, M., Inda, M.M., Wykosky, J., Bachoo, R.M., James, C.D., DePinho, R.A., Vandenberg, S.R., Zhou, H., Marie, S.K., Mischel, P.S., Cavenee, W.K., Furnari F.B. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240. PNAS, 109: 14164-14169, 2012.
Latha, K., Li, M., Chumbalkar, V., Gururaj, A., Hwang, Y.H., Dakeng, S., Saway, R., Aldape, K., Cavenee, W.K., Bogler, O., Furnari F.B. Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter. Int. J. Cancer, 132: 509-520 (2013).
Read, R.D., Fenton, T.R., Gomez, G.G., Wykosky, J., Vandenberg, S.R., Babic, I., Iwanami, A., Yang, H., Cavenee, W.K., Mischel, P.S., Furnari, F.B., Thomas, J.B. A kinome-wide RNAi screen in Drosophila glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma. PLoS Genetics, 9: May, 2013.
Iwanami, A., Gini, B., Zanca, C., Matsutani, T., Assuncao, A., Nael, A., Dang, J., Yang, H., Zhu, S., Kohyama, J., Kitabayashi, I., Cavenee, W.K., Cloughesy, T.F., Furnari, F.B., Toyama, Y., Okano, H., Mischel, P.S. PML mediates glioblastoma resistance to target of rapamycin (mTOR)-targeted therapies. PNAS, 110: 4339-44, 2013.
Gini, B., Zanca, C., Guo, D., Matsutani, T., Masui, K., Ikegami, S., Yang, H., Nathanson, D., Villa, G., Shackelford, D., Zhu, S., Tanaka, K., Babic, I., Akhavan, D., Lin, K., Assuncao, A., Gu, Y., Bonetti, B., Mortensen, D.S., Xu, S., Raymon, H., Cavenee, W.K., Furnari, F.B., James, C.D., Kroemer, G., Heath, J.R., Hege, K., Chopra, R., Cloughesy, T.F., Mischel, P.S. The mTOR kinase inhibitor, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clin Cancer Res., 19:5722-32 (2013).
Nathanson, D.A., Gini, B., Mottahedeh, J., Visnyei, K., Koga,. T., Gomez, G., Eskin, A., Hwang, K., Wang, J., Masui, K., Paucar, A., Yang, H., Ohashi, M., Zhu, S., Wykosky, J., Reed, R., Nelson, S.F., Cloughesy, T.F., James, C.D., Rao, P.N., Kornblum, H.I.*, Heath, J.R.*, Cavenee, W.K.*, Furnari, F.B.*, Mischel. P.S*. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. (* equal contribution). Science, 343: 72-76 (2014).
Gomez, G. G., Volinia, S., Croce. C. M., Zanca, C., Li, M., Emnett, R., Gutmann, D. H., Brennan, C. W., Furnari, F. B*., and Cavenee, W. K. Suppression of MicroRNA-9 by Mutant EGFR Signaling Upregulates FOXP1 to Enhance Glioblastoma Tumorigenicity. (* corresponding author). Cancer Research, 74: 192-205 (2014).
Li, J., Zhu, S., Kozono, D., Ng, K., Futalan, D., Shen, Y., Akers, J.C., Steed, T., Kushwaha, D., Schlabach, M., Carter, B.S., Kwon, C.H., Furnari, F., Cavenee, W, Elledge, S., Chen, C.C. Genome- wide shRNA screen revealed integrated mitogenic signaling between dopamine receptor D2 (DRD2) and epidermal growth factor receptor (EGFR) in glioblastoma. Oncotarget, 5: 882-93 (2014).
Feng, H., Hu, B., Vuori, K., Sarkaria, J.N., Furnari, F.B., Cavenee, W.K., Cheng, S.Y. EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180. Oncogene, 33: 2504-2512 (2014).
Feng, H., Lopez, G.Y., Kim, C.K., Alvarez, A., Duncan, C.G., Nishikawa, R., Nagane, M., Su, A.J., Auron, P.E., Hedberg, M.L., Wang, L., Raizer, J.J., Kessler, J.A., Parsa, A.T., Gao, W.Q., Kim, S.H., Minata, M., Nakano, I., Grandis, J.R., McLendon, R.E., Bigner, D.D., Lin, H.K., Furnari, F.B., Cavenee, W.K., Hu, B., Yan, H., Cheng, S.Y. EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis. J. Clin. Invest, 124: 3741-56 (2014).
Hu, J., Muller, K.A., Furnari, F.B., Cavenee, W.K., VandenBerg, S.R., Gonias, S.L. Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell- signaling. Oncogene, 34: 4078-88 (2015).
Wykosky, J., Hu, J., Gomez, G.G., Taylor, T., Villa, G.R., Pizzo, D., VandenBerg, S.R., Thorne, A.H., Chen, C.C., Mischel, P.S., Gonias, S.L., Cavenee, W.K., Furnari, F.B. A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer Research, 75: 394-404 (2015).
Costa, E., Barnabé, G., Li, M., Dias, A., Machado, T., Asprino, P., Cavalher, F., Ferreira, E., Inda, M. D. M., Nagai, M., Malnic, B., Carraro, D., Chammas, R., Leite, K., Barros, A., Armelin, H., Cavenee, W., Furnari, F., Duarte, M., Camargo, A. Intratumoral heterogeneity of ADAM23 promotes tumor growth and metastasis through LGI4 and nitric oxide signals. Oncogene, 34: 1270-1279 (2015).
Antal, C.E., Hudson, A.M., Kang, E., Zanca, C., Wirth, C., Stephenson, N.L., Trotter, E.W., Gallegos, L.L., Miller, C.J., Furnari, F.B., Hunter, T., Brognard, J., Newton, A.C. Cancer- Associated Protein Kinase C Mutations Reveal Kinase's Role as Tumor Suppressor. Cell, 160: 489-502 (2015).
Shen, Y., Li, J., Nitta, M., Futalan, D., Steed, T., Treiber, J.M., Taich, Z., Stevens, D., Wykosky, J., Chen, H.-Z., Carter, B.S., Becher, O.J., Kennedy, R., Esashi, F., Sarkaria, J.N., Furnari, F.B., Caveneee, W.K., Desai, A., Chen, C.C. Orthogonal targeting of EGFRvIII expressing glioblastomas through simultaneous EGFR and PLK1 inhibition. Oncotarget, 6:11751-67 (2015).
Liu, F., Hon, G.C., Villa, G.R., Turner, K.M., Ikegami, S., Yang, H., Ye, Z., Li, B., Kuan, S., Lee, A.Y., Zanca, C., Wei, B., Lucey, G., Jenkins, D., Zhang, W., Barr, C.L., Furnari, F.B., Cloughesy, T.F., Yong, W.H., Gahman, T.C., Shiau, A.K., Cavenee, W.K., Ren, B., Mischel, P.S. EGFR Mutation Promotes Glioblastoma Through Epigenome and Transcription Factor Network Remodeling. Mol. Cell, 60: 307-318 (2015).
Tsuchihashi, K., Okazaki, S., Ohmura, M., Ishikawa, M., Sampetrean, O., Onishi, N., Wakimoto, H., Yoshikawa, M., Seishima, R., Iwasaki, Y., Morikawa, T., Abe, S., Takao, A., Shimizu, M., Masuko, T., Nagane, M., Furnari, F.B., Akiyama, T., Suematsu, M., Baba, E., Akashi, K., Saya, H., Nagano. O. The EGF receptor promotes the malignant potential of glioma by regulating amino acid transport system xc(-). Cancer Res. 76: 2954-2963, 2016.
Villa, G.R., Hulce, J.J., Zanca, C., Bi, J., Ikegami, S., Cahill, G.L., Gu, Y., Lum, K.M., Masui, K., Yang, H., Rong, X., Hong, C., Turner, K.M., Liu, F., Hon, G.C., Jenkins, D., Martini, M., Armando, A.M., Quehenberger, O., Cloughesy, T.F., Furnari, F.B., Cavenee, W.K., Tontonoz, P., Gahman, T.C., Shiau, A.K., Cravatt, B.F., Mischel, P.S. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell. 30: 683-693, 2016.
Chou, S-T., Patil, R., Galstyana, A., Gangalum, P.R., Cavenee, W.K., Furnari, F.B., Ljubimov, V.A., Chesnokova, A., Kramerov, A.A., Ding, H., Falahatian, V., Mashouf, L., Fox, I., Black, K.L., Holler, E., Ljubimov, A.V., Ljubimova, J.Y. Simultaneous blockade of interacting CK2 and EGFR pathways by tumor-targeting nanobioconjugates increases therapeutic efficacy against glioblastoma multiforme. J. Control Release. 244: 14-23, 2016.
Kegelman, T.P., Wu, B., Das, S.K., Talukdar, S., Beckta, J.M., Hu, B., Emdad, L., Valerie, K., Sarkar, D., Furnari, F.B., Cavenee, W.K., Wei, J., Purves, A., De, S.K., Pellecchia, M., Fisher, P.B. Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin. PNAS, 114: 370-375, 2017.
Turner, K.M., Deshpande, V., Beyter, D., Koga, T., Rusert, J., Lee, C., Li, B., Arden, K., Ren, B., Nathanson, D., Cavenee, W.K., Wechsler-Reya, R., Furnari, F., Vandenberg, S.R., Rao, N., Wahl, G.M., Bafna, V., Mischel, P.S. Extrachromosomal oncogene amplification drives tumor evolution and the development of genetic heterogeneity in human cancer. Nature. 543: 122-125, 2017.
Benitez, J.A., Ma, J., D’Antonio. M., Boyer, A., Camargo, M.F., Zanca, C., Kelly, S., Khodadadi- Jamayran, A., Jameson, N.M., Andersen, M., Miletic, H., Saberi, S., Frazer, K.A., Cavenee, W.K., Furnari, F.B. PTEN regulates glioblastoma oncogenesis through chromatin-associated complexes of DAXX and histone H3.3. Nature Comm. 8: 15223, 2017.
Zanca, C., Villa, G.R., Benitez, J.A., Thorne, A. H., Koga, T., D’Antonio, M., Ikegami, S., Ma, J., Boyer, A.D., Eliseeva, O. V., Barnabe, G.F., Liu, F., Wu, S., Yang, H., Wykosky, J., Frazer, K.A., Verkhusha, V.V., Isaguliants, M.G., Weiss, W.A., Gahman, T.C., Shiau, A.K., Chen, C.C., Mischel, P.S., Webster K. Cavenee, W.K., Frank B. Furnari, F.B. Glioblastoma cellular crosstalk converges on NF-κB to attenuate EGFR inhibitor sensitivity. Genes & Development. 31: 1212- 1227, 2017.
Reviews and Book Chapters: Furnari, F. B., and Pagano, J. S. Induction and Regulation of Expression of the Epstein-Barr Virus DNA Polymerase Gene. In Epstein-Barr Virus and Human Disease 1990. (D.V. Ablashi et al., ed.), The Humana Press, Inc., Totowa, N.J., pp. 117-121,1991
Pagano, J. S., Sista, N.D., Furnari, F. B., and Lin, J. C. Expression and Regulation of the Epstein-Barr Virus DNA Polymerase. Biotechnology of Cell Regulation, Serono Symposia Series, Advances in Experimental Medicine, (R. Verna and Y. Nishizuka, editors), Raven Press, New York, 4:153-168, 1991.
Furnari, F. B., Adams, M. D., and Pagano, J. S. The 3' ends of EBV DNA Polymerase mRNAs are Processed Without Canonical Polyadenylation Signals. In Epstein-Barr Virus and Associated Disease 1993. (T. Tursz et al., ed.), John Libbey and Company Ltd, London, England, pp.175- 180.
Furnari, F. B., Huang, H.-J. S., Cavenee, W. K. Genetics and malignant progression of human brain tumors. Cancer Surveys 25: 233-275, 1995
Furnari, F. B., Huang, H.-J. S., Cavenee, W. K. Molecular biology of malignant degeneration of astrocytoma. Pediatr Neurosurg 24: 41-49, 1996.
Cavenee, W. K., Furnari, F. B., Nagane, M., Huang, H.-J. S., Newcomb, E. W., Bigner, D. D., Weller, M., Plate, K., Israel, M., Noble, M. Diffuse infiltrating astrocytomas. In Pathology and Genetics of Tumours of the Nervous System, Second Edition. (P. Kleihues and W. Cavenee, eds.) IARC Press, Lyon, France, pp. 9-21, 2000.
Maher, E., Furnari, F., Bachoo, R., Rowitch, D., Louis, D., Cavenee, W. Malignant Glioma: Genetics and Biology of a Grave Matter. Genes and Development 15:1311-1333, 2001.
Furnari, F. B. and Cavenee, W. K. PTEN: a tumor suppressor with lipid and protein phosphatase activity. In Encyclopedia of Cancer, Second Edition. (J. R. Bertino ed.) Academic Press, San Diego, CA., 2001.
Okumura, K., Zhao, M., DePinho, R. A., Furnari, F. B., Cavenee, W. K. PTEN: A novel anti- oncogenic function independent of phosphatase activity. Cell Cycle, 4: 540-542, 2005.
Furnari, F. B., Fenton, T, Bachoo, R. M., Mukasa, A. Stommel, J. M., Stegh, A., Hahn, W. C,. Ligon, K. L., Louis, D. N., Brennan, C., Chin, L., DePinho, R. A., Cavenee, W. K. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes and Development 21: 2683- 710, 2007.
Huang, P. H., Cavenee, W. K., Furnari, F. B., White, F. M. Uncovering Therapeutic Targets FOR Glioblastoma: A Systems Biology Approach. Cell Cycle, 6: 1-5, 2007.
Stokoe, D., Furnari F. B. The PTEN/PI3kinase Pathway in Human Glioma. In CNS Cancer, Models, Prognostic Factors and Targets. (E. Van Meir ed.). Springer, New York, 2009.
Wykosky, J., Mukasa, A., Furnari, F., Cavenee, W. K. Escape from Targeted Inhibition: the Dark Side of Kinase Inhibitor Therapy. Cell Cycle, 16: 1661-1662, 2010.
Wykosky, J., Fenton, T., Furnari, F., Cavenee, W. K. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chinese Journal of Cancer, 30:5-12, 2011.
Bonavia, R., Inda, M-d-M., Cavenee, W., Furnari, F. Heterogeneity Maintenance in Glioblastoma: a social network. Cancer Research, 71: 4055-4060, 2011.
Taylor, TE., Furnari F.B., Cavenee,W.K. Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome Resistance. Curr Cancer Drug Targets, Jan, 2012.
Gutmann, D. H., Stiles, C. D., Lowe, S. W., Bollag, G. E., Furnari, F. B., Charest, A. Report from the fifth national cancer institute mouse models of human cancers consortium nervous system tumors workshop. Neuro Oncol. 13: 692-699, 2011.
Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., Agarwalla, P. K., Chheda, M. G., Campos, B., Wang, A., Brennan, C., Ligon, K. L., Furnari, F., Cavenee, W. K., Depinho, R. A., Chin, L., Hahn, W. C. Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev. 26: 756-84, 2012.
Masui, K., Gini, B., Wykosky, J., Zanca, C., Mischel, P.S., Furnari, F., Cavenee, W. A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next generation cancer treatments. Carcinogenesis. 34: 725-38, 2013.
Gomez, G.G., Wykosky, J., Zanca, C., Furnari, F.B., Cavenee, W.K. Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks. Caner Biol. Med. 10: 192-205, 2013.
Pulido, R., Baker, S.J., Barata, J.T., Carracedo, A., Cid, V.J., Chin-Sang, I.D., Davé, V., den Hertog, J., Devreotes, P., Eickholt, B.J., Eng, C., Furnari, F.B., Georgescu, M.M., Gericke, A., Hopkins, B., Jiang, X., Lee, S.R., Lösche, M., Malaney, P., Matias-Guiu, X., Molina, M., Pandolfi, P.P., Parsons, R., Pinton, P., Rivas, C., Rocha, R.M., Rodríguez, M.S., Ross, A.H., Serrano, M., Stambolic, V., Stiles, B., Suzuki, A., Tan, S.S., Tonks, N.K., Trotman, L.C., Wolff, N., Woscholski, R., Wu, H., Leslie, N.R. A Unified Nomenclature and Amino Acid Numbering for Human PTEN. Sci Signal, 332: pe15 (2014).
Furnari, F.B., Cloughesy, T.F., Cavenee, W.K., Mischel, P.S. Heterogeneity of Epidermal Growth Factor Receptor signaling networks in glioblastoma: implications for drug resistance. Nature Reviews Cancer. 15:302-10, 2015.
Thorne A.H., Zanca, C. Furnari, F. Epidermal growth factor receptor targeting and challenges in glioblastoma. Neuro Oncol. In Press, 2016.
Patents: Johns, T. G., Perera, R. M., Vernes, S. C., Vitali, A. A., Cao, D. X., Cavenee, W. K., Andrew M. Scott, A. M., Furnari, F. B. Treatment Method Using EGFR Antibodies and src Inhibitors and Related Formulations. Provisional patent application LUD 5981, filed March 15, 2007.
Sah, D., Tan, P., Inda, MdM., Furnari, F., Cavenee, W., Bonavia, R. Compositions and Methods for Inhibiting Expression of Mutant EGFR Gene. 26205971.1-1401
Other Experience and Professional Memberships: 1990-1993 International Association for Research on EBV and Associated Diseases 1990-1993 American Society for Microbiology 1993-Present: American Association for Cancer Research 1998-Present: Society for Neuro-Oncology 3/01-present: Associate member UCSD Cancer Center 1/07-present: Neuro-Oncology Editorial Board member 9/07-present: American Society for Biochemistry and Molecular Biology 2009-present: Faculty Member Biomedical Sciences Graduate Program, UCSD 2009-present: National Brain Tumor Society Advisory Board Member 2010 Goldhirsh Foundation Advisory Board Member 2010-present: Stand Up to Cancer Advisory Board Member 2011-present: European Association for Cancer Research- Active Member 2013-present: Tissue Distribution Committee Member- UCSD-Neuropathology 2013 Neuro-Oncology Editor Selection Committee 2013-present: UCSD BMS graduate program admissions committee member 2013-present: Molecular Cancer Research Editorial Board member 11/13-present: Neuro-Oncology Associate Editor 2014: Elected Society of Neuro-Oncology Basic Science Representative 2016- present DF/HCC Brain SPORE External Advisory Committee member 2016- present Curtana Pharmaceutical Scientific Advisory Board 2017- present Sontag Foundation Scientific Advisory Board
Review Panels: NCI Subcommittee-D PO1 ad hoc reviewer: 9/02, 9/03, 10/03, 9/04, 12/04 NCI Tumor Progression and Metastasis study section Ad HOC reviewer: 6/05-12/06 Medical Research Council grant Ad HOC reviewer: 6/04 ACS Institutional Research Grant Review Committee UCSD Cancer Center: 11/04-present NCI Cancer Genetics study section Ad Hoc reviewer: 2/10 Italian Association for Cancer Research (AIRC) review committee: 2011-present Royal Colleges of Surgeons in Ireland (RCSI) Research Institute Ad Hoc reviewer: 2013 OBT IRG Special Emphasis Panel Ad Hoc reviewer: 2015 Scientific Retreat of TGen’s Cancer & Cell Biology Division: 2015 NCI subcommittee IV- PO1 ad hoc reviewer: 2/17
Invited lectures: Hiroshima Cancer Seminar Foundation: “Dissecting the de2-7EGFR Transcriptome in Glioma” (lectured and chaired session): Hiroshima, Japan, 11/10/02
Emory University: “Intrinsic and Extrinsic Mechanisms of Mutant EGFR Enhancement of Glioma Tumorigenicity” (lectured): Atlanta, GA, 8/29/03
LICR-Melbourne: “Functional Analysis of PTEN and Mutant EGFR in Glioma” (lectured): Melbourne, Australia, 10/04
Society for Neuro-Oncology Annual Meeting: “Glioma Genomes, Pathology and Models” (poster session summary presentation): Toronto, Canada, 11/04
University of Pittsburgh: “Functional Analysis of PTEN and Mutant EGFR in Glioma” (lectured): Pittsburgh, PA, 11/04
MD Anderson Cancer Center: “Regulation of PI3K Signaling and Transformation by PTEN C- terminal-interacting Proteins” (lectured): Houston, TX, 4/05
Mouse Models of Cancer (Wash Univ): “Mutant EGFR and Tumor Maintenance” (lectured): St. Louis, MO, 6/05
Massachusetts General Hospital: “The Role of EGF Receptor Heterogeneity in Driving Glioma Development” (lectured): Boston, MA, 4/06
La Jolla Institute for Molecular Medicine: “The Role of EGF Receptor Heterogeneity in Driving Glioma Development” (lectured): La Jolla, CA, 4/06
Goldhirsh Foundation: “The Role of EGF Receptor Heterogeneity in Driving Glioma Development and Therapeutic Responsiveness” (poster), Boston, MA, 5/06
Cold Spring Harbor PTEN meeting: “ Regulation of PI3K Signaling and Transformation by PTEN C-Terminal-Interacting Proteins” (lecture), Cold Spring Harbor, NY, 3/08
Genomics and Biology of GBM, a TCGA Workshop: (invited participant), Bethesda, MD 3/08
17th International Conference on Brain Tumor Research and Therapy: “The Role of EGF Receptor Heterogeneity in Driving Glioma Development” (lecture), Hakodate, Japan 6/08.
University of North Carolina-Chapel Hill: “ Regulation of PI3K Signaling and Transformation by PTEN C-Terminal-Interacting Proteins” (lecture), Chapel Hill, NC 9/08
MD Anderson Cancer Center: “ Regulation of PI3K Signaling and Transformation by PTEN C- Terminal-Interacting Proteins” (lecture), Houston, TX 11/08
UCSD-Hillcrest Biomedical and Clinical Research Seminar series: “Targeting the EGFR/P13K Pathway in GBM: Determinants of Therapeutic Sensitivity” (lecture), San Diego, CA 3/09
LICR Brain Tumor Meeting- “Targeting the EGFR/PI3K Pathway in Glioblastoma: Determinants of Therapeutic Sensitivity” (lecture), Rockville, MD 9/09
UCSD-Neuro-Oncology Program Conference, Moores Cancer Center: “Intrinsic and extrinsic function of mutant EGFR in glioma” (lecture), La Jolla, CA 1/10
Goethe University Medical School Institute of Neurology (Edinger Institute): “Intrinsic and extrinsic function of mutant EGFR in glioma” (lecture), Frankfurt, Germany 5/10
18th International Conference on Brain Tumor Research and Therapy: “ Tumor Heterogeneity in Glioblastoma is an Active Process Driven by a Mutant EGFR-Induced Paracrine Circuit” (lecture), Travemünde, Germany 5/10.
Society for Neuro-oncology annual meeting: Tumor Heterogeneity is an Active Process Driven by a Mutant EGFR-Induced Paracrine Circuit in GBM: (lecture), Montreal, Canada 11/10.
Memorial Sloan Kettering Cancer Center: “Function of Mutant EGFR in Maintaining Glioblastoma Growth and Heterogeneity” (lecture), New York, NY 12/10.
Brain Tumors:1st Annual Collaborative Care Conference (UCSD): “Tumor Heterogeneity in GBM is an Active Process Maintained by a Mutant EGFR-Induced Cytokine Circuit” (lecture), La Jolla, CA 1/15/11.
Lorne Cancer Conference: Tumor Heterogeneity is an Active Process Driven by a Mutant EGFR-Induced Paracrine Circuit in Glioblastoma: (lecture), Lorne, Australia 2/11.
UCSD Department of Pathology: “Function of Mutant EGFR in Maintaining Glioblastoma Growth and Heterogeneity” (lecture), La Jolla, CA 2/28/11.
University of Toronto: “Heterogeneity in Glioblastoma: a driver of tumor growth and therapeutic resistance” (lecture), Toronto, CA 6/9/11.
LICR Oxford meeting: “Heterogeneity in Glioblastoma: a driver of tumor growth” (lecture), Oxford, England 9/11
Institute of Cancer Research: “Heterogeneity in Glioblastoma: a driver of tumor growth and therapeutic resistance” (lecture), London, England 9/11.
Society for Neuro-oncology annual meeting: PTEN phosphorylation by fibroblast growth factor receptors and SRC mediates resistance to epidermal growth factor receptor inhibitors in glioblastoma: (lecture), Anaheim, CA 11/11.
Indian Society for Neuro-Oncology: "PTEN phosphorylation by fibroblast growth factor receptors and SRC mediates resistance to epidermal growth factor receptor inhibitors in glioma" (lecture), Bangalore, India 4/12
Indian Institute of Science: “Genotypic Interactions in Glioma Heterogeneity” (lecture), Bangalore, India 4/12
UC-Irvine: “PTEN phosphorylation by fibroblast growth factor receptors and SRC mediates resistance to epidermal growth factor receptor inhibitors in GBM” (lecture), Irvine, CA, 5/12
Ludwig Stanford Stem Cell Meeting: “Genotypic Interactions in Glioma Heterogeneity” (lecture), Stanford, CA, 5/12
19th International Brain Tumor Research and Therapy Conference: “PTEN phosphorylation by fibroblast growth factor receptors and SRC mediates resistance to epidermal growth factor receptor inhibitors in glioblastoma” (lecture), Niagara Falls, Ontario 6/12
Seve Ballesteros Foundation Special Conference on Brain Cancer: “PI3K/Akt Pathway- dependent and -independent Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Glioblastoma” (lecture), Barcelona, Spain, 7/12
22nd European Association for Cancer Research: “PTEN phosphorylation by fibroblast growth factor receptors and SRC mediates resistance to epidermal growth factor receptor inhibitors in glioblastoma” (lecture), Barcelona, Spain, 7/12
CSHL Brain Tumors course: “EGF Receptors in Glioma Biology: Therapeutic Targets and Multifaceted Drivers of Pathogenicity” (lecture), Cold Spring Harbor, NY, 7/12
ISNO/ASNO: “Therapeutic resistance to EGFR inhibitors” (lecture), Mumbai, India, 3/13
Moores Cancer Center noon lecture: “Therapeutic resistance to EGFR inhibitors in glioblastoma” (lecture), La Jolla, CA, 4/13
University of Calgary: “EGF Receptor in Glioma Biology: Therapeutic Target and a Multifaceted Driver of Pathogenicity” (lecture), Calgary, Canada, 5/13
Canyon Crest Academy High School: “My Career as a Scientist” (lecture), San Diego, CA 5/13
Montreal International Symposium on Angiogenesis and Metastasis: “Molecular and cellular heterogeneity as a hallmark of brain tumours” (lecture), Montreal, Canada, 6/13
Cancer Centers Council Inaugural Scientific Retreat: “ GBM studies facilitated through the biorepository and tissue technology shared resource” (lecture), La Jolla, CA, 6/13
LICR Oxford meeting: “Mechanisms of upfront and acquired resistance to EGFR kinase inhibitors in glioblastoma”, Oxford, England 9/13
University College of London Cancer Institute: EGF Receptor in Glioma Biology: Therapeutic Target and a Multifaceted Driver of Pathogenicity (lecture), London, England 9/13
Institute of Cancer Research: EGF Receptor in Glioma Biology: Therapeutic Target and a Multifaceted Driver of Pathogenicity (lecture), London, England 9/13.
UCSD Cancer Cell Biology training grant lecture: EGF Receptor in Glioma Biology: Therapeutic Target and a Multifaceted Driver of Pathogenicity (lecture), La Jolla, CA, 12/13
National Brain Tumor Society Bran Tumor Walk Kick-off Event: Advances in Brain Cancer Research in the Mesa (short talk), La Jolla, CA 3/14
Cincinnati Children’s Hospital: EGF Receptor in Glioma Biology: Therapeutic Target and a Multifaceted Driver of Pathogenicity (lecture), Cincinnati, OH 3/14
Emory University: EGF Receptor in Glioma Biology: A Multifaceted Driver of Pathogenicity and Therapeutic Target, Atlanta, GA 6/14
International Conference on Brain Tumor Research and Therapy (ICBTRT): Mutant EGFR Suppression of MicroRNA-9 Induces FOXP1 to Enhance Glioblastoma Tumorigenicity (lecture), Lake Tahoe, CA 7/14
Duke University: EGF Receptor in Glioma Biology: A Multifaceted Driver of Pathogenicity and a Therapeutic Target, Durham, NC 8/14
CSHL Brain Tumor Course 2014: EGF Receptors in Glioma Biology: Therapeutic Target and Multifaceted Drivers of Pathogenicity, Cold Spring Harbor, NY 8/14
Asian Society for Neuro-Oncology: EGFR Signaling and Targeted Therapeutics in Glioblastoma, Istanbul, Turkey 9/14
NBTS Summit: Defeat GBM Meeting: Target Discovery, Boston, MA 10/14
University of Bergen: EGF Receptor in Glioma Biology: A Multifaceted Driver of Pathogenicity and Therapeutic Target, Bergen, Norway 10/14
The 6th Dependence Receptor Meeting: Tumor Microenvironment, Signaling and Dependence: EGFR Heterogeneity Drives Glioma Growth and Therapeutic Resistance, Tianjin, China 4/15
Dana-Farber/Harvard Cancer Center Neuro-Oncology Program Retreat: EGFR Signaling and Targeted Therapeutics in Glioblastoma, Boston, MA 4/15
Wake Forest School of Medicine, Brain Tumor Center of Excellence: EGFR Heterogeneity Drives Glioma Growth and Therapeutic Resistance, Winstom-Salem, NC 6/15
EACR/AACR/SIC meeting: Tumor heterogeneity contributes to anti-EGFR therapy resistance in glioblastoma, Florence, Italy 6/15
University of Alabama at Birmingham, EGFR Heterogeneity Drives Glioma Growth and Therapeutic Resistance 9/15
Society for Neuro-Oncology annual meeting: Tumor heterogeneity contributes to anti-EGFR therapy resistance in glioblastoma. San Antonio, TX 11/15
Society for Neuro-Oncology annual meeting: Tyrosine phosphorylation of nuclear PTEN promotes therapeutic resistance through enhanced DNA damage repair. San Antonio, TX 11/15
International Conference on Brain Tumor Research and Therapy (ICBTRT): Tyrosine phosphorylation of nuclear PTEN promotes therapeutic resistance through enhanced DNA damage repair (lecture), Okinawa, Japan 4/16
MD Anderson: 2016 Deborah M. Richman Lecture: Novel function of PTEN in the nucleus: what’s a nice lipid phosphatase doing in a place like this? Houston, TX 6/16
CSHL Brain Tumor Course 2016: Targeting the EGFR/PTEN Signaling Axis in Glioblastoma, Cold Spring Harbor, NY 8/16
University of Turku: Therapeutic Targeting the EGFR/PTEN Signaling Axis in Glioblastoma, Turko, Finland, 8/16
Society for Neuro-Oncology annual meeting: Tyrosine phosphorylation of nuclear PTEN promotes therapeutic resistance through DNA damage repair. Phoenix, AZ 11/16
Society for Neuro-Oncology annual meeting: Tumor heterogeneity contributes to anti-EGFR therapy resistance in glioblastoma. San Francisco, CA 11/17
Teaching: SOM204: Cell Biology & Biochemistry- reading class director for 1st year Medical and 2nd year Pharmacy students NEU268: Molecular and Cellular Neurobiology- lecturer PATH221: The Molecular Pathology of Cancer- lecturer BIOM252: Human Genetics and Genomics- course director and lecturer BIOM201: Seminars in Biomedical Research- discussion leader
Trainees: PhD thesis committees: Ee-Tsin Wong (Geoff Wahl advisor)- PhD granted 2007 Nate Heizman (Bing Ren advisor)- PhD granted 2008 Megan Bird (Terry Mulhern, advisor; University of Melbourne) Aaron Gajadhar (Abhijit Guha, advisor; University of Toronto)- PhD granted 2010 Karen A Tumaneng (Kun-Liang Guan advisor)- PhD granted 2013 Charles Thomas (Alysson Muotri advisor)- PhD granted 2014 Tiffany Taylor (Frank Furnari, advisor)- PhD granted 2016 Catherine Lee (Robert Wechsler-Reya, advisor)- PhD granted 2016 Shannon Muir (Karen Arden, advisor)- PhD granted 2014 Tania Escobar (Marion Sewer, advisor)- M.S. granted 2014 Eskil Hakon Eskilsson (Hrvoje Miletic, advisor; University of Bergen)- PhD granted 2014 Amanpreet Kaur (Jukka Westermarck, advisor: University of Turku)- PhD granted 2016 Brian Reilly (Rafael Bejar, advisor) Kimberly Lin (Kun-liang Guan, advisor) An-Angela Van (Alexandra Newton, advisor)
BMS Graduate Students: Michelle Mendoza (research Advisor from 4/01 to 12/02) Tiffany Taylor (rotation student Fall 2009) Melissa Wilbert (minor proposition committee member Fall 2009) Tiffany Taylor (thesis advisor from 7/10-9/16) Catherine Lee (minor proposition committee member Fall 2011) Christopher Abdullah (minor proposition committee member Fall 2011) Elizabeth Kleinschmidt (rotation student Winter 2012) Jeff Rodvold (rotation student Spring 2012) Alexandra Buckley (thesis advisor from 9/13-9/14) Nathan Jameson (thesis advisor from 6/14-present) Timothy Baffi (minor proposition committee member Fall 2014) Alison Parisian (thesis advisor from 6/15-present) Afsheen Banisadr (co-thesis advisor with Dr. Adam Engler from 6/15-present) Kimberly Lin (minor proposition committee member Fall 2015) Hannah Majeski (SPAC advisor 2013-present) Emily Wheeler (SPAC advisor 2014-present) Gregory Golden (SPAC advisor 2015-present) Emily Griffin (SPAC advisor 2016-present) Kira Podolsky (SPAC advisor 2016-present) Melinda Beccari (SPAC advisor 2017-present) Caila Pilo (minor proposition committee member Fall 2017)
Postdoctoral Fellows: Current position Yoshitaka Narita 8/00-11/02 Assoc. Prof., U of Tokyo Yen-Liang Chen 8/00-12/03 Asst. Prof., Univ. of Singapore Koichi Okumura 1/01-5/06 Senior Scientist, Nat’l U. Singapore Xinyi Lin 9/03-3/06 Postdoc, Burnham Inst. Akitake Mukasa 11/02-6/07 Assoc. Prof., Neurosurgery, U of Tokyo Rudy Bonavia 4/03-7/10 Asst. Investigator, Vall D’Hebron Inst. of Oncology Tim Fenton 2/05- 5/11 Lecturer in Molecular Biosciences, U of Kent Maria del Mar Inda 5/05-6/11 Project and Publication Manager, General Hospital of Alicante, Spain German Gomez 7/06-4/14 Research Scientist, IGE Therapeutics & Pharmaceuticals, San Diego Ming Li 8/06-12/12 Asst. Investigator, VCU Jill Wykosky 6/08-10/13 Research Scientist, Takeda Pharm. Gabriela Barnabe 4/14-5/15 Postdoc, LICR at HSL, São Paulo, SP – Brazil Jorge Benitez 6/08-present Circo Zanca 4/10-present Jianhui Ma 2/13-present Tomoyuki Koga 4/13-present Amy Hasely-Thorne 4/14-11/17 Scientist, Inovio Pharmaceuticals, San Diego Tiffany Taylor 10/16-12/16 Christine Mirzayan Science & Technology fellow
Visiting Scientist: Professor Karl Plate Sabbatical Host from 3/08-6/08 Professor Hrvoje Miletic Sabbatical Host from 4/15-7/15
Active Research Support: Laboratory Support (Furnari-PI) Since 07/01/1997 Ludwig Institute for Cancer Research Support is not targeted to specific projects. The current focus of the work supported by LICR, however, is the role that late stage glioma mutations play in tumor progression.
5R01NS080939-01 (Furnari-PI) 9/1/2012-5/31/2018 NCI/NINDS Genotypic Interactions in Brain Cancer Heterogeneity. Glioblastoma multiforme (GBM), the most common primary brain tumor in adults is a highly invasive, neurologically destructive tumor with a survival range of 12-15 months. A central issue that contributes to this lack of successful treatment is the tumor’s heterogeneous composition. This proposal aims to identify the genes and mechanisms that promote GBM heterogeneity. These insights will lead to new tools for improving the efficacy of known therapeutic agents as well as for the development of new therapeutic approaches.
Defeat GBM Project 1- Discovery (Furnari-PI) 2/1/2014- 1/31/2019 National Brain Tumor Association This project will define glioma-specific mechanisms of resistance to TKI’s directed at EGFR or other RTK’s.
Rady Children’s Hospital Foundation Pedal for the Cause (Furnari-PI) 7/1/2017-6/30/2018 Tissue-specific role of SMARCB1 in pediatric rhabdoid tumors This project aims to identify the mechanisms underlying initiation of pediatric rhabdoid tumors of the kidney and atypical teratoid rhabdoid tumors (ATRT) of the brain, which result from deletion of the SMARCB1 gene.
Recent Completed Research: JSMF 220020319 (Furnari-PI) 10/01/2012 – 09/30/2016 James S. McDonnell Foundation EGFR Inhibitor Resistance in Glioblastoma: Deciphering the Role of FGFR-Mediated PTEN Phosphorylation This grant examined the mechanism of upfront and acquired resistance to EGFR tyrosine kinase inhibitors in gliomas retaining wild type PTEN expression.
2 P01 CA095616-06 (DePinho-PI) 03/01/2008 – 02/29/2013 Dana Farber Cancer Institute/NCI Genetics and Biology of Malignant Glioma (Project 2: EGFR and PTEN in Mouse and Human Gliomas) This was an inter-institutional program project between the Ludwig Institute and the Dana Farber Cancer Institute. Its purpose was to investigate the genetic defects underlying the initiation, progression, and maintenance of gliomas. Role: Co-PI
Pending: 5R01NS080939-01 (Furnari-PI) 4/1/2018-3/31/2023 NCI/NINDS Genotypic Interactions in Brain Cancer Heterogeneity.
UC San Diego Stem Cell Program (Furnari-PI) 8/1/2017-7/30/2018 Generation of Cancer Models from Human Induced Pluripotent Stem Cells. In this project we will test if hiPSCs, engineered with specific combinations of mutations introduced by CRISPR/Cas9-mediated genome editing, give rise to tumor models that faithfully recapitulate biology, genetic progression and gene expression signatures of each cancer type in question.